Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherRevenue (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Abeona Therapeutics (ABEO) Shares Outstanding (2016 - 2025)

Abeona Therapeutics has reported Shares Outstanding over the past 16 years, most recently at $55.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 20.59% year-over-year to $55.0 million; the TTM value through Dec 2025 reached $55.0 million, up 20.59%, while the annual FY2025 figure was $55.0 million, 20.59% up from the prior year.
  • Shares Outstanding for Q4 2025 was $55.0 million at Abeona Therapeutics, up from $52.4 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $55.0 million in Q4 2025 and troughed at $4.0 million in Q1 2021.
  • A 5-year average of $25.6 million and a median of $23.1 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: tumbled 95.26% in 2021 and later soared 265.87% in 2023.
  • Year by year, Shares Outstanding stood at $5.9 million in 2021, then surged by 200.94% to $17.7 million in 2022, then surged by 49.69% to $26.5 million in 2023, then skyrocketed by 72.09% to $45.6 million in 2024, then rose by 20.59% to $55.0 million in 2025.
  • Business Quant data shows Shares Outstanding for ABEO at $55.0 million in Q4 2025, $52.4 million in Q3 2025, and $51.2 million in Q2 2025.